Phenolic compounds ameliorate the glucose uptake in HepG2 cells' insulin resistance via activating AMPK Anti-diabetic effect of phenolic compounds in HepG2 cells

被引：93

作者：

Huang, Qun ^{[1
]}

Chen, Lei ^{[1
]}

Teng, Hui ^{[1
]}

Song, Hongbo ^{[1
]}

Wu, Xiaoqi ^{[1
]}

Xu, Meiyu ^{[1
]}

机构：

[1] Fujian Agr & Forestry Univ, Coll Food Sci, Fuzhou 350002, Fujian, Peoples R China

来源：

JOURNAL OF FUNCTIONAL FOODS | 2015年 / 19卷

关键词：

Phenolics; HepG2; insulin resistance; AKT pathway; AMPK; MAKUWA MAKINO SEED; IN-VITRO; PROTEIN-KINASE; MODELS; HYPERGLYCEMIA; LIPOTOXICITY; HEPATOCYTES; METABOLISM; MECHANISMS; FLAVONOIDS;

D O I：

10.1016/j.jff.2015.09.020

中图分类号：

TS2 [食品工业];

学科分类号：

100403 [营养与食品卫生学];

摘要：

The preventive effects of phenolic compounds on insulin signalling and on both glucose production and uptake were studied in insulin-responsive human HepG2 cells treated with high glucose. The influence of insulin in different-dose insulin and at different action times on the IR of HepG2 cells, and changes of glucose uptake and glycogen level were detected by using cell culture glucose uptake analysis. Seven compounds, agrimonolide (1), desmethylagrimonolide (2), quercetin (3), luteolin (4), luteolin-7-O-glucoside (5), kaempferol (6), and apigenin (7), were used. The IR model was successfully established in HepG2 cells after the action of 5 x 10(-7) M insulin for 24 h. The analysis of glucose uptake showed that 1-3 samples had significant glucose lowering activity and exhibited no difference with metformin (P >0.05). All compounds had low cytotoxicity in HepG2 cells within the test concentration. Compounds 1 and 2 pre-treatment also prevented the inactivation of the AKT pathway and AMPK, which play an important role in glycometabolism. (C) 2015 Published by Elsevier Ltd.

引用

页码：487 / 494

页数：8

共 31 条

[1]

[Anonymous], BIOORG MED CHEM LETT

[2]

ASANO T, 2006, Patent No. 2006016388

[3]

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines [J].